Residual beta-cell function results in better glycemic control, less microvascular complications and less hypoglycemia. And consequently, marked clinical benefit might result from preserving the higher levels of C-peptide observed in patients with surveillance versus community diagnosis of type 1 diabetes. In addition C-peptide itself may have biologic effects, most of which are proposed to be beneficial.